Skip to main content

Dexcom launches G7 continuous glucose monitor

Smaller than its predecessor, the G7 may benefit children and adults using multiple daily injections and those who experience hypo unawareness.
JDRF logo placeholder for author profile picture
Kate Lawton 6 October 2022

A woman and girl using a Dexcom G7 continuous glucose monitor

What’s new about the G7 CGM?

The G7 is the latest version of Dexcom’s range of continuous glucose monitors (CGM).

The G7 is 60% smaller than the previous model, the G6. It also warms up more quickly, so you can start to use it after 30 minutes.

It also has an integrated sensor and transmitter, which makes it easier to apply, and unlike the G6, the G7 is fully disposable. The G7 has improved accuracy and can be worn in more places; on the upper arm, abdomen, or – for children aged between 2 and 6 – on their upper buttocks.

The G7 has improved alert settings and has a redesigned receiver that is smaller but with a display that is easier to read. The mobile app has also been redesigned and simplified. Plus, there is a 12 hour ‘grace period’ giving greater flexibility on when you need to replace the CGM.

How it works with other tech

Many CGMs are compatible with insulin pumps to create a hybrid closed loop system which automates insulin delivery.

The G7 is currently not compatible with insulin pumps, so it can’t be used as part of a hybrid closed-loop system (also known as the artificial pancreas). However, there are plans to develop this capability in the future.

Who will benefit from the G7?

CGMs are used to monitor glucose levels in real-time, throughout the day and night, and relieve the burden of having to do multiple finger prick tests throughout the day.

Although the G7 can’t form part of a closed loop system, it may be beneficial for children and adults who use multiple daily injections of insulin and want to use a CGM to monitor their glucose levels. It’s also recommended for people who find it difficult to recognise the signs and symptoms of a hypo, known as hypo unawareness.

How can I get a G7?

If your healthcare professional feels that you would get a specific benefit from using the G7 rather than other CGMs, they will be able to order one for you.

Related news

Read more
Illustration of the hybrid closed loop technology system, funded as part of treatment research for type 1 diabetes by JDRF.
14 November 2021

Landmark clinical agreement supporting DIY artificial pancreas systems is published

A landmark international agreement on the treatment and support for people living with type 1 diabetes using Do-it-Yourself (DIY) artificial pancreas technology has been published today.

Read more
A man doing flash glucose monitoring
Type 1 technology
25 November 2021

Draft NICE guidelines propose wider access to glucose monitoring tech

JDRF is delighted that the National Institute for Healthcare and Care Excellence (NICE) has published draft guidelines recommending that all adults with type 1 diabetes should be offered a choice of flash or continuous glucose monitoring (CGM) in England.

Read more
The artificial pancreas
Type 1 technology
4 February 2022

Closed-loop systems to be considered for all who could benefit in Scotland

JDRF is delighted to have contributed to a new report, published in January 2022, which has issued recommendations for NHS Scotland, aimed at widening access to closed-loop systems for all people with type 1 diabetes in Scotland.

Read more
A man showing his glucose monitor - a key treatment and technology for type 1 diabetes
Type 1 technology
31 March 2022

Everyone with type 1 diabetes will be offered flash or CGM technology free on the NHS in England and Wales.

New guidance for the NHS in England published today has recommended that people with type 1 diabetes be offered a choice of flash monitoring or continuous glucose monitoring (CGM) on the NHS.